Adlarity (Donepezil HCl) Patent Expiration, LOE Window & CMS Spending
Adlarity (Donepezil HCl) by Corium/Prasco L: FDA Orange Book core substance LOE 2036-12-30 (last listed 2038-08-11), 22 AB generics, $2.6M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Corium/Prasco L |
| FDA Application & Pathway | N212304 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2036-12-30 |
| Last Listed Patent or Exclusivity Date | 2038-08-11 |
| Orange Book Patents (*PED Extensions) | 11 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 22 |
| 2024 CMS Total Public Spend | $2.6M |
| 2024 Medicare Part D Spend | $2.5M |
| 2024 Medicaid Spend | $125K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |